Guanylate Cyclase Activators Influence Reactivity of Human Mesenteric Superior Arteries Retrieved and Preserved in the Same Conditions as Transplanted Kidneys

Transplantation Proceedings

Volumn 39, Issue 5, 2007, Pages 1350-1353

  Slupski, M ^a   Szadujkis Szadurski, L ^a   Grzesk G ^a   Szadujkis Szadurski, R ^a   Szadujkis Szadurska, K ^a   Wlodarczyk, Z ^a   Masztalerz, M ^a   Piotrowiak, I ^a   Jasinski M ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (4 CARBOXYPHENYL) 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CARBOXY 2 [4 CARBOXYPHENYL] 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; ESTER DERIVATIVE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; N NITRO L ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; OUABAIN; POTASSIUM CHANNEL; SCAVENGER; SEROTONIN; UNCLASSIFIED DRUG;

ARTERY DILATATION; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; KIDNEY TRANSPLANTATION; MESENTERIC ARTERY; PRIORITY JOURNAL; VASODILATATION;

BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; INDAZOLES; KIDNEY TRANSPLANTATION; MESENTERIC ARTERY, SUPERIOR; NG-NITROARGININE METHYL ESTER; ORGAN PRESERVATION; OXADIAZOLES; PLATELET AGGREGATION INHIBITORS; QUINOXALINES; RETROSPECTIVE STUDIES; VASODILATION; VASODILATOR AGENTS;

EID: 34250362762     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.02.079     Document Type: Article

References (15)

1. Wilhelm S.M., Simonson M.S., Robinson A.V., et al. Endothelin up-regulation and localization following renal ischemia and reperfusion. Kidney Int 55 (1999) 1011
2. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109
3. Lucas K.A., Pitari G.M., Kazerounian S., et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52 (2000) 375
4. Ko F.N., Wu C.C., Kuo S.C., et al. YC-1, a novel activator of platelet guanylate cyclase. Blood 84 (1994) 4226
5. Wu C.C., Ko F.N., Kuo S.C., et al. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116 (1995) 1973
6. Mulsch A., Bauersachs J., Schafer A., et al. Effect of YC1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120 (1997) 681
7. Hoenicka M., Becker E.M., Apeler H., et al. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med 77 (1999) 14
8. Friebe A., Mullershausen F., Smolenski A., et al. YC1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54 (1998) 962
9. Becker E.M., Schmidt P., Schramm M., et al. The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. J Cardiovasc Pharmacol 35 (2000) 390
10. Teixeira C.E., Priviero F.B.M., and Webb R.C. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyri midin-4 ylamine] and YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole]. J Pharmacol Exp Ther 317 (2006) 258
11. Wohlfart P., Malinski T., Ruetten H., et al. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br J Pharmacol 128 (1999) 1316
12. Galle J., Zabel U., Hubner U., et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127 (1999) 195
13. Wang J.P., Chang L.C., Huang L.J., et al. Inhibition of extracellular Ca2+ entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. Biochem Pharmacol 62 (2001) 679
14. Bawankule D.U., Sathishkumar K., Sardar K.K., et al. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1Hpyrazolo[3,4-b]pyridine-3-yl]pyr imidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump. J Pharmacol Exp Ther 314 (2005) 207
15. Rothermund L., Friebe A., Paul M., et al. Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br J Pharmacol 130 (2000) 205